Herein, we report a case of metastatic B2 thymoma refractory to platinum chemotherapy with high PD‐L1 expression (60%), who was treated with camrelizumab, resulting in serious immune‐related adverse events (irAEs) after administration of the first cycle. Here, CD274 is linked to thymoma.